Canine Melena: Localization and Gastrointestinal Bleeding Workup

Bottom line

Melena is a phenotype—digested blood in feces—not a final localization or etiology. Confirm that the stool is genuinely black and tar-like, assess perfusion and hemorrhage severity before pursuing source localization, and build the workup around medication exposure, systemic disease, hemostasis, and evidence of focal gastrointestinal pathology. A normal abdominal ultrasound or a nonspecific urea-to-creatinine ratio does not exclude clinically important mucosal bleeding.

Stabilize before localization

Assess mentation, heart rate and pulse quality, mucous membranes, capillary refill, temperature, respiratory effort, blood pressure, and serial packed cell volume or hematocrit with total solids. Place vascular access and type or crossmatch when ongoing hemorrhage or clinically important anemia is plausible. Use lactate and point-of-care ultrasound according to stability and the broader shock differential.

Escalate monitoring for collapse, progressive anemia, hematemesis, tachycardia, hypotension, abdominal pain, coagulopathy, or suspected perforation. The absence of visible melena during hospitalization does not prove bleeding has stopped; stool reflects prior transit and fasting may limit output.

Confirm the phenotype and history

Examine stool or owner photographs when possible. Distinguish melena from dark diet-related stool and bismuth, activated charcoal, iron, or ingested soil. Ask about hematemesis, epistaxis, oral bleeding, hemoptysis, and dietary blood sources because swallowed blood can mimic primary GI hemorrhage. Rectal examination may identify distal blood, masses, foreign material, or concurrent hematochezia.

Construct a precise medication timeline: NSAIDs, corticosteroids, anticoagulants, antiplatelet drugs, supplements, and accidental human-drug exposure. Determine whether different household members administered overlapping products. Review renal, hepatic, endocrine, inflammatory, neoplastic, and prior GI disease; trauma; foreign-body and toxin risk; travel and parasite prevention.

Initial laboratory assessment

A CBC with smear review can identify anemia pattern, reticulocyte response, platelet estimate, inflammatory change, and iron-restricted indices in chronic loss. Interpret PCV serially because acute hemorrhage and fluid therapy alter values. Chemistry and urinalysis assess renal and hepatic contributors, protein loss, bilirubin, and competing sources of azotemia.

Use PT, aPTT, fibrinogen, D-dimer or viscoelastic testing according to the case. Coagulation testing moves forward when bleeding is multisite, bruising or thrombocytopenia is present, toxin exposure is plausible, or invasive procedures are planned. Fecal parasite testing and disease-specific infectious testing depend on age, exposure, geography, and immune status.

An increased urea-to-creatinine ratio should not be treated as proof of upper GI bleeding. In a study of dogs with overt and occult hemorrhage, the ratio did not reliably identify occult bleeding or distinguish upper from lower lesions.[2] Use it as contextual data rather than a localization shortcut.

Imaging, endoscopy, and lesion detection

Survey radiographs may identify foreign material, obstruction, free gas, mass effect, or an alternative abdominal process. Ultrasound can evaluate wall layering, focal masses, lymph nodes, perforation, liver, pancreas, kidneys, and peritoneum, but Merck notes low sensitivity for nonperforated GI ulcers.[1]

After stabilization, endoscopy provides direct visualization of the esophagus, stomach, proximal duodenum, and colon and permits targeted biopsy. Sample ulcer margins cautiously when perforation risk is relevant. Endoscopic absence of a lesion does not end the workup when anemia or overt bleeding persists. Capsule endoscopy or advanced imaging may be appropriate in referral settings; canine capsule-endoscopy data show angiodysplasia can be missed by conventional endoscopy or exploratory surgery.[3]

Consider exploratory surgery when perforation, obstruction, devitalized bowel, uncontrolled focal hemorrhage, or a surgically actionable lesion is suspected. Align the procedure with hemostatic status and stabilization goals.

Differential framework

Group causes as mucosal injury or ulceration, neoplasia, vascular lesions, foreign body or obstruction, infectious or parasitic disease, systemic hypoperfusion, hemostatic disorders, swallowed blood, and drug-associated injury. Gastric and duodenal ulcers may produce nonspecific vomiting, anorexia, abdominal pain, or weight loss, and melena or hematemesis can be absent even with confirmed ulceration.[1]

When there is no focal lesion, revisit severe systemic illness, renal or hepatic disease, adrenal disease where clinically appropriate, sepsis, mast-cell disease, and medication combinations. Avoid labeling an incidental imaging abnormality as the bleeding source without anatomic and temporal support.

Treatment and reassessment

Stop suspected ulcerogenic drugs when medically appropriate and document future contraindications. Correct perfusion deficits, clinically important anemia, electrolyte abnormalities, and coagulopathy. Choose acid suppression, mucosal protection, antiemetic therapy, nutrition, antimicrobials, antidotes, or procedural treatment according to mechanism rather than reflexively stacking drugs.

Trend mentation, perfusion, abdominal pain, emesis, fecal appearance, PCV or hematocrit, total solids, platelets, and relevant chemistry values. Define thresholds for transfusion, repeat imaging, endoscopy, surgery, and referral. The consumer melena guide, vomiting blood guide, and pale gums guide support owner observation and escalation.

Frequently Asked Questions

Does melena always localize bleeding to the upper GI tract?

It strongly supports digested blood but is not anatomically absolute. Transit time, bleeding rate, swallowed blood, and lesions beyond the stomach or proximal small intestine can complicate localization.

Is an increased urea-to-creatinine ratio diagnostic of upper GI bleeding?

No. Prospective and retrospective canine data show insufficient discrimination for occult bleeding or upper-versus-lower localization. Interpret it only within the full clinical picture.

When should coagulation testing be prioritized?

Prioritize it when there is bruising, bleeding from multiple sites, rodenticide exposure, severe hepatic disease, thrombocytopenia, planned invasive sampling, or hemorrhage disproportionate to a focal GI lesion.

Can a normal ultrasound exclude a GI ulcer?

No. Ultrasound may reveal wall changes, masses, perforation, or non-GI disease, but sensitivity for nonperforated mucosal ulceration is limited.

When is endoscopy most useful?

It is useful after stabilization when direct mucosal assessment and biopsy can change management, particularly with persistent overt bleeding, suspected ulceration, or unexplained anemia.

Should every dog with melena receive empiric gastroprotection?

Treat the patient and suspected mechanism, not the stool color alone. Stabilization and removal of ulcerogenic factors are central; drug selection should follow current evidence and contraindications.